FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions: Neurofibromatosis 1; Plexiform Neurofibroma; NF1 Interventions: Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;; Drug: Control group (Group B): Placebo, orally, once daily; Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials